VEA
PGNX
Virtus ETF Advisers’s Progenics Pharmaceuticals Inc PGNX Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q2 | – | Sell |
-71,758
| Closed | -$273K | – | 493 |
|
|
2020
Q1 | $273K | Sell |
71,758
-10,475
| -13% | -$39.9K | 0.11% | 237 |
|
|
2019
Q4 | $419K | Buy |
82,233
+20,460
| +33% | +$104K | 0.07% | 242 |
|
|
2019
Q3 | $312K | Sell |
61,773
-3,441
| -5% | -$17.4K | 0.06% | 195 |
|
|
2019
Q2 | $402K | Buy |
+65,214
| New | +$402K | 0.08% | 191 |
|
|
2019
Q1 | – | Sell |
-64,532
| Closed | -$271K | – | 293 |
|
|
2018
Q4 | $271K | Buy |
64,532
+12,534
| +24% | +$52.6K | 0.05% | 147 |
|
|
2018
Q3 | $326K | Sell |
51,998
-38,179
| -42% | -$239K | 0.03% | 180 |
|
|
2018
Q2 | $725K | Buy |
+90,177
| New | +$725K | 0.64% | 88 |
|
|
2017
Q4 | – | Sell |
-148,929
| Closed | -$1.1M | – | 276 |
|
|
2017
Q3 | $1.1M | Hold |
148,929
| – | – | 0.15% | 55 |
|
|
2017
Q2 | $1.01M | Buy |
148,929
+33,629
| +29% | +$228K | 0.15% | 65 |
|
|
2017
Q1 | $1.09M | Buy |
115,300
+11,087
| +11% | +$105K | 0.19% | 60 |
|
|
2016
Q4 | $900K | Sell |
104,213
-31,127
| -23% | -$269K | 0.27% | 71 |
|
|
2016
Q3 | $857K | Buy |
135,340
+17,055
| +14% | +$108K | 0.41% | 38 |
|
|
2016
Q2 | $499K | Buy |
118,285
+14,478
| +14% | +$61.1K | 0.37% | 59 |
|
|
2016
Q1 | $453K | Hold |
103,807
| – | – | 0.62% | 45 |
|
|
2015
Q4 | $636K | Buy |
+103,807
| New | +$636K | 1.75% | 12 |
|